O
Orhan Aktas
Researcher at University of Düsseldorf
Publications - 205
Citations - 10758
Orhan Aktas is an academic researcher from University of Düsseldorf. The author has contributed to research in topics: Multiple sclerosis & Neuromyelitis optica. The author has an hindex of 43, co-authored 176 publications receiving 7988 citations. Previous affiliations of Orhan Aktas include Technische Universität München & Max Delbrück Center for Molecular Medicine.
Papers
More filters
Journal ArticleDOI
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
Sven Jarius,Klemens Ruprecht,Brigitte Wildemann,Tania Kuempfel,Marius Ringelstein,Christian Geis,Ingo Kleiter,Ingo Kleiter,Christoph Kleinschnitz,Achim Berthele,Johannes Brettschneider,Kerstin Hellwig,Bernhard Hemmer,Ralf A. Linker,Ralf A. Linker,Florian Lauda,Christoph Mayer,Hayrettin Tumani,Arthur Melms,Corinna Trebst,Martin Stangel,Martin Marziniak,Frank Hoffmann,Sven Schippling,Jürgen H. Faiss,Oliver Neuhaus,Barbara Ettrich,Christian Zentner,Kersten Guthke,Ulrich Hofstadt-van Oy,Reinhard Reuss,Hannah L. Pellkofer,Ulf Ziemann,Peter Kern,Klaus Peter Wandinger,Florian Then Bergh,Tobias Boettcher,Stefan Langel,Martin Liebetrau,Paulus S. Rommer,Sabine Niehaus,Christoph Münch,Alexander Winkelmann,Uwe K Zettl U,Imke Metz,Christian Veauthier,Jörn P Sieb,C. Wilke,Hans Hartung,Orhan Aktas,Friedemann Paul +50 more
TL;DR: This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.
Journal ArticleDOI
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)
Corinna Trebst,Sven Jarius,Achim Berthele,Friedemann Paul,Friedemann Paul,Sven Schippling,Brigitte Wildemann,Nadja Borisow,Ingo Kleiter,Orhan Aktas,Tania Kümpfel +10 more
TL;DR: The Neuromyelitis Optica Study Group (NEMOS) summarizes recently obtained knowledge on NMO and highlights new developments in its diagnosis and treatment, based on current guidelines, the published literature and expert discussion at regular NEMOS meetings.
Journal ArticleDOI
MOG encephalomyelitis: International recommendations on diagnosis and antibody testing
Sven Jarius,Friedemann Paul,Friedemann Paul,Orhan Aktas,Nasrin Asgari,Russell C. Dale,J. de Seze,Diego Franciotta,Kazuo Fujihara,Anu Jacob,Ho Jin Kim,Ingo Kleiter,T. Kümpfel,Michael J. Levy,Jacqueline Palace,Klemens Ruprecht,Albert Saiz,Corinna Trebst,Brian G. Weinshenker,Brigitte Wildemann +19 more
TL;DR: In this article, the authors proposed indications for MOG-IgG testing based on expert consensus, and gave a list of conditions atypical for MG-EM (red flags) that should prompt physicians to challenge a positive MOG IgG test result, and provided recommendations regarding assay methodology, specimen sampling and data interpretation.
Journal ArticleDOI
Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress
Ulrike Seifert,Lukasz P. Bialy,Frédéric Ebstein,Dawadschargal Bech-Otschir,Antje Voigt,Friederike Schröter,Timour Prozorovski,Nicole Lange,Janos Steffen,Melanie Rieger,Ulrike Kuckelkorn,Orhan Aktas,Peter-M. Kloetzel,Elke Krüger +13 more
TL;DR: It is shown that i-proteasomes function to protect cell viability under conditions of IFN-induced oxidative stress, and it is found that the ubiquitylation machinery is concomitantly upregulated in response to IFNs, functioning to target defective ribosomal products (DRiPs) for degradation by i- Proteasome.
Journal ArticleDOI
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Bruce A.C. Cree,Jeffrey Bennett,Ho Jin Kim,Brian G. Weinshenker,Sean J. Pittock,Dean M. Wingerchuk,Kazuo Fujihara,Friedemann Paul,Gary Cutter,Romain Marignier,Ari J. Green,Orhan Aktas,Hans-Peter Hartung,Fred D. Lublin,Jorn Drappa,Gerard Barron,Soraya Madani,John N. Ratchford,Dewei She,Daniel Cimbora,Eliezer Katz,N-MOmentum study investigators +21 more
TL;DR: Compared with placebo, inebilizumab reduced the risk of an NMOSD attack and has potential application as an evidence-based treatment for patients withNMOSD.